[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preimplantation-genetic-testing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preimplantation-genetic-testing":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100464314","phase-3-comparison-of-the-euploid-rate-of-blastocyst-between-ppos-and-gnrh-antagonist-protocol-in-women-with-pcos-undergoing-pgt-a-100464314",false,"NCT05326087","Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A","A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the PPOS (Progestin-primed Ovarian Stimulation) Protocol and the Gonadotropin-releasing Hormone (GnRH) Antagonist Protocol in Women With PCOS (Polycystic Ovary Syndrome) Undergoing PGT-A (Preimplantation Genetic Testing for Aneuploidy)","Inclusion Criteria:\n\n* Women age between 20 and 37 years.\n* Women diagnosed with PCOS according to the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of ≥12 antral follicles (≤9 mm) and\u002For ovarian volume \\>10 mL on transvaginal ultrasonographic scanning, and\u002For clinical\u002F biochemical hyperandrogenism. Other causes of hyperandrogenism and ovulation dysfunction-including tumours, congenital adrenal hyperplasia, hyperprolactinaemia and thyroid dysfunction-were excluded\n\nExclusion Criteria:\n\n* Presence of a functional ovarian cyst with E2\\>100 pg\u002FmL\n* Endometriosis grade 3 or higher\n* Repeated implantation failure (\\>=4 embryos replaced or \\>=2 blastocysts replaced without success)\n* Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)\n* Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease;\n* Recipient of oocyte donation\n* Presence of hydrosalpinx which is not surgically treated","FEMALE","20 Years","37 Years",{"count":20,"type":21},204,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:\n\nAntagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.\n\nPPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger.\n\nThe primary outcome is the euploidy rate of blastocysts.",[27,28,29,30],"Preimplantation Genetic Testing","Progestin-primed Ovarian Stimulation","Polycystic Ovarian Syndrome","GnRH Antagonist","NOT_YET_RECRUITING","2026-01-29",{"date":34,"type":35},"2026-02-02","ACTUAL",{"date":37,"type":21},"2026-06-01",{"date":39,"type":21},"2028-12-01",{"name":41,"class":42},"ShangHai Ji Ai Genetics & IVF Institute","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100529596","phase-4-ppos-progestin-primed-ovarian-stimulation-and-corifollitropin-alfa-cfa-cross-over-study-100529596","NCT06175832","PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study","PPOS and CFA for Elective Freeze-all Ovarian Stimulation Cycles: a Prospective Cross-over Study","P-CCROSS","Prescreening: Clarification: Pre-screening might be performed to identify women with AFC \\> 5 and AMH \\> 1.1 ng\u002Fml (Bologna criteria, AFC and AMH values are valid for one year).\n\nInclusion criteria for:\n\n* Group 1: indication for oocyte cryopreservation\n* Group 2: indication for IVF\u002FICSI and PGT-A\n\nInclusion criteria for both groups:\n\n* First ovarian stimulation cycle\n* Aged ≥ 18 and \\\u003C 41 years old at the time of first OPU\n\nExclusion Criteria:\n\n* contra-indication for ovarian stimulation\n* expected poor ovarian response (Bologna Criteria)\n* PCOS patients\n* refusal to fill out questionnaires before, during and after treatment\n* simultaneous participation in another clinical study\n* untreated and uncontrolled thyroid dysfunction;\n* current use of oral contraceptives, anti-psychotics, anti-epileptics or chemotherapy;\n* pregnant or breastfeeding women. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.","18 Years","40 Years",{"count":54,"type":21},60,[56],"PHASE4","P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH\u002FGnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA\u002FPPOS versus rFSH\u002FGnRH ovarian stimulation cycles.",[59,60,27,61],"Ovarian Stimulation","Quality of Life","Fertility Preservation","RECRUITING","2025-12-18",{"date":65,"type":35},"2025-12-26",{"date":67,"type":35},"2025-01-27",{"date":69,"type":21},"2027-12-31",{"name":71,"class":42},"University Hospital, Ghent",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":72},"100473616","phase-3-effect-of-gh-on-the-blastocyst-euploid-rate-in-ama-patients-100473616","NCT05447208","Effect of GH on the Blastocyst Euploid Rate in AMA Patients","A Randomized Control Trial to Investigate the Effect of Growth Hormone on the Euploid Rate of Blastocyst in Patients With Advanced Maternal Age","Inclusion Criteria:\n\n* Age ≥38; intended to undergo PGT-A\n* BMI in the normal range (18.50-24.0kg\u002Fm2)\n* Normal semen analysis for the male partner\n\nExclusion Criteria:\n\n* Endometriosis grade 3 or higher, untreat hydrosalpinx\n* Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)\n* Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease\n* History of endocrine disorder, autoimmune diseases or diagnosed thrombophilia\n* History of GH supplementation in the previous IVF treatment or taking other supplementary drugs used during stimulation; patients with absolute or relative contraindications to GH treatment, including active malignancy or history of cancer, diabetic retinopathy, diabetes mellitus, and chronic kidney disease.","38 Years",{"count":82,"type":21},400,[24],"This randomized trial aims to compare the euploid rate of blastocysts in AMA patients undergoing PGT-A (preimplantation genetic testing for aneuploidy) with or without growth hormone supplement.\n\nInfertile patients ≥38 years old will be recruited for study after informed consent if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:\n\nTreatment group: Women will receive growth hormone (GH) supplement before and during antagonist protocol for ovarian stimulation.\n\nControl group: Women will receive antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts.",[27,86,87],"Growth Hormone","Age, Parental","2025-02-07",{"date":90,"type":35},"2025-02-12",{"date":92,"type":35},"2022-08-01",{"date":94,"type":21},"2026-12-31",{"name":41,"class":42}]